Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 3/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
| ▸ | MAP4K1 | Q92918 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CNR1 | P21554 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | NR1H2 | P55055 | 6/20 | 0.41 |
| ▸ | NR1H3 | Q13133 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15294552 | 0.86 | NR1H2 (0.48) | CNR2HDAC6CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL4065436 | 0.85 | CNR2 (0.46) | CNR2HDAC6CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL13406308 | 0.85 | NR1H2 (0.47) | CNR2HDAC6CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL10197702 | 0.85 | HDAC6 (0.61) | CNR2HDAC6CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL14838247 | 0.84 | CYP1A2 (0.47) | CNR2HDAC6CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL4073633 | 0.84 | NR1H2 (0.55) | CNR2HDAC6CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL14300652 | 0.83 | CYP1A2 (0.46) | CNR2HDAC6CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL30814318 | 0.82 | LMNA (0.41) | CYP3A4NR1H2MAPT | |
| SCHEMBL368032 | 0.82 | CYP1A2 (0.45) | CNR2HDAC6CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL21651845 | 0.82 | CYP1A2 (0.45) | CNR2HDAC6CYP1A2CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1317445-B1 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS | ANORMED INC (CA) | 2009-03-11 | — | — | EP | disclosed |
| US-7396840-B2 | Chemokine receptor binding heterocyclic compounds | GENZYME CORPORATION (US) | 2008-07-08 | — | — | US | disclosed |
| US-7084155-B2 | Chemokine receptor binding heterocyclic compounds | ANORMED (CA) | 2006-08-01 | — | — | US | disclosed |
| US-20060128750-A1 | Chemokine receptor binding heterocyclic compounds | GENZYME CORPORATION | 2006-06-15 | — | — | US | disclosed |
| US-6864265-B2 | Chemokine receptor binding heterocyclic compounds | ANORMED, INC. (CA) | 2005-03-08 | — | — | US | disclosed |
| US-20040220207-A1 | Chemokine receptor binding heterocyclic compounds | GENZYME CORPORATION | 2004-11-04 | — | — | US | disclosed |
| EP-1317445-A2 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS | ANORMED INC. (CA) | 2003-06-11 | — | — | EP | disclosed |
| US-20030018046-A1 | Chemokine receptor binding heterocyclic compounds | GENZYME CORPORATION | 2003-01-23 | — | — | US | disclosed |
| WO-2002022600-A2 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS | ANORMED INC. (CA) | 2002-03-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040220207-A1 | Chemokine receptor binding heterocyclic compounds | CXCR3, ACKR3, CCR2 | CNR2 168/4885HDAC6 805/4885MAP4K1 1476/4885 |
| US-20060128750-A1 | Chemokine receptor binding heterocyclic compounds | CXCR4, CCR5, CXCR3 | CNR2 127/4885HDAC6 828/4885MAP4K1 2042/4885 |
| US-20030018046-A1 | Chemokine receptor binding heterocyclic compounds | CXCR3, ACKR3, CCR2 | CNR2 168/4885HDAC6 805/4885MAP4K1 1476/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.